medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-634Research ArticleСтатьиСовременные опции и перспективы системной терапии метастатической увеальной меланомы. Обзорная статьяModern options and perspectives of systemic therapy of metastatic uveal melanoma. Review articleЖуликовЯ. А.ZhulikovYa. A.noemail@neicon.ruДемидовЛ. В.DemidovL. V.noemail@neicon.ruСинельниковИ. Е.SinelnikovI. E.noemail@neicon.ruНазароваВ. В.NazarovaV. V.noemail@neicon.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I. M. SechenovRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N. N. BlokhinRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I. M. Sechenov; National Medical Research Centre of Oncology n.a. N. N. BlokhinRussian Federation201816052018115Диагностика и онкотерапия2024Copyright © Жуликов Я.А., Демидов Л.В., Синельников И.Е., Назарова В.В., 20182018Жуликов Я.А., Демидов Л.В., Синельников И.Е., Назарова В.В.Zhulikov Y.A., Demidov L.V., Sinelnikov I.E., Nazarova V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/634

Увеальная меланома (УМ) - опухоль, развивающаяся из меланоцитов увеального тракта. На данный момент нет ни одной опции лекарственной терапии, повышающей общую выживаемость пациентов с метастатической УМ. Последние исследования значительно улучшили понимание биологических особенностей УМ, что может помочь в персонализации терапии. В данном обзоре будут описаны биологические особенности, современные лекарственные опции и перспективы в лечении метастатической УМ.

Uveal melanoma (UM) is a rare malignance tumor, which arise from melanocytes of the uveal tract. Now there is no options of the systemic therapy that increase the overall survival of patients with metastatic UM. Recent researches significantly improved our understanding of biology feature UM, what can help in personalization of the treatment. In this review we will consider biology features, modern options and future treatment strategies of metastatic UM.

увеальная меланомаиммунотерапияанти-PD-1таргетная терапияuveal melanomaimmunotherapyanti-PD-1target therapyReferencesSingh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881-1885. PMID: 2 1704381 DOI: 10.1016/]. ophtha.2011.01.040.Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881-1885. PMID: 2 1704381 DOI: 10.1016/]. ophtha.2011.01.040.Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83 (8): 1664-1678. PMID: 9781962.Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83 (8): 1664-1678. PMID: 9781962.Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44 (11): 4651-4659. PMID: 14578381.Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44 (11): 4651-4659. PMID: 14578381.Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012; 38 (5): 549-553. PMID: 22270078. DOI: 10.1016/j.ctrv.2012.01.002.Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012; 38 (5): 549-553. PMID: 22270078. DOI: 10.1016/j.ctrv.2012.01.002.Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012; 18 (2): 148-152. PMID: 22453016. DOI: 10.1097/PP0.0b013e31824bd256.Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012; 18 (2): 148-152. PMID: 22453016. DOI: 10.1097/PP0.0b013e31824bd256.Smit KN, van Poppelen NM, Vaarwater J, et al. Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma. Mod Pathol. 2018. PMID: 29327717. DOI: 10.1038/modpathol.2017.187.Smit KN, van Poppelen NM, Vaarwater J, et al. Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma. Mod Pathol. 2018. PMID: 29327717. DOI: 10.1038/modpathol.2017.187.Jager MJ, Dogrusöz M, Woodman SE. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia Pac J Ophthalmol (Phila). 2017; 6 (2): 179-185. PMID: 28399339. DOI: 10.22608/APO.201782.Jager MJ, Dogrusöz M, Woodman SE. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia Pac J Ophthalmol (Phila). 2017; 6 (2): 179-185. PMID: 28399339. DOI: 10.22608/APO.201782.Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7 (4): 281-294. PMID: 17384583. DOI: 10.1038/nrc2110.Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7 (4): 281-294. PMID: 17384583. DOI: 10.1038/nrc2110.Yu FX, Luo J, Mo JS, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25 (6): 822-830. PMID: 24882516. DOI: 10.1016/j. ccr.2014.04.017.Yu FX, Luo J, Mo JS, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25 (6): 822-830. PMID: 24882516. DOI: 10.1016/j. ccr.2014.04.017.Schmidt S, Debant A. Function and regulation of the Rho guanine nucleotide exchange factor Trio. Small GTPases. 2014; 5: e29769. PMID: 24987837. DOI: 10.4161/sgtp.29769.Schmidt S, Debant A. Function and regulation of the Rho guanine nucleotide exchange factor Trio. Small GTPases. 2014; 5: e29769. PMID: 24987837. DOI: 10.4161/sgtp.29769.Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311 (23): 2397-2405. PMID: 24938562. DOI: 10.1001/jama.2014.6096.Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311 (23): 2397-2405. PMID: 24938562. DOI: 10.1001/jama.2014.6096.Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13 (8): 782-789. PMID: 22805292. DOI: 10.1016/S 1470-2045(12)70269-3.Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13 (8): 782-789. PMID: 22805292. DOI: 10.1016/S 1470-2045(12)70269-3.Piperno-Neumann S, Kapiteijn L, Larkin J et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB 071 in patients with metastatic uveal melanoma. Journal of Clinical Oncology 2014 32:15_suppl, 9030-9030. DOI: 10.1200/ jco.2014.32.15_suppl.9030.Piperno-Neumann S, Kapiteijn L, Larkin J et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB 071 in patients with metastatic uveal melanoma. Journal of Clinical Oncology 2014 32:15_suppl, 9030-9030. DOI: 10.1200/ jco.2014.32.15_suppl.9030.Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 2006; 24 (2): 288-295. PMID: 16344319. DOI: 10.1200/JCO.2005.02.2418.Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 2006; 24 (2): 288-295. PMID: 16344319. DOI: 10.1200/JCO.2005.02.2418.Shoushtari A, Kudchadkar R, Panageas K et al. A randomized phase 2 study of trametinib with or without GSK2 141795 in patients with advanced uveal melanoma. Journal of Clinical Oncology 2016 34:15_suppl, 9511-9511. DOI: 10.1200/ JCO.2016.34.15_suppl.9511.Shoushtari A, Kudchadkar R, Panageas K et al. A randomized phase 2 study of trametinib with or without GSK2 141795 in patients with advanced uveal melanoma. Journal of Clinical Oncology 2016 34:15_suppl, 9511-9511. DOI: 10.1200/ JCO.2016.34.15_suppl.9511.Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011; 17 (8): 2087-2100. PMID: 21444680. DOI: 10.1 158/1078-0432. CCR-10-3169.Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011; 17 (8): 2087-2100. PMID: 21444680. DOI: 10.1 158/1078-0432. CCR-10-3169.Daud A, Kluger HM, Kurzrock R, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozan-tinib in metastatic melanoma. Br J Cancer. 2017; 116 (4): 432-440. PMID: 28103611. DOI: 10.1038/bjc.2016.419.Daud A, Kluger HM, Kurzrock R, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozan-tinib in metastatic melanoma. Br J Cancer. 2017; 116 (4): 432-440. PMID: 28103611. DOI: 10.1038/bjc.2016.419.Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009; 28 (5): 329-347. PMID: 19563908. DOI: 10.1016/j.preteyeres.2009.06.002.Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009; 28 (5): 329-347. PMID: 19563908. DOI: 10.1016/j.preteyeres.2009.06.002.Bronkhorst IH, Jager MJ. Inflammation in uveal melanoma. Eye (Lond). 2013; 27 (2): 217-223. PMID: 23238448. DOI: 10.1038/ eye.2012.253.Bronkhorst IH, Jager MJ. Inflammation in uveal melanoma. Eye (Lond). 2013; 27 (2): 217-223. PMID: 23238448. DOI: 10.1038/ eye.2012.253.de la Roche M, Asano Y, Griffiths GM. Origins of the cytolytic synapse. Nat Rev Immunol. 2016; 16 (7): 421-432. PMID: 27265595. DOI: 10.1038/nri.2016.54.de la Roche M, Asano Y, Griffiths GM. Origins of the cytolytic synapse. Nat Rev Immunol. 2016; 16 (7): 421-432. PMID: 27265595. DOI: 10.1038/nri.2016.54.Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997; 38 (9): 1865-1872. PMID: 9286277.Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997; 38 (9): 1865-1872. PMID: 9286277.Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42 (10): 2153-2156. PMID: 11527924.Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42 (10): 2153-2156. PMID: 11527924.Hallermalm K, Seki K, De Geer A et al. Modulation of the Tumor Cell Phenotype by IFN-y Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes. The Journal of Immunology March 15, 2008, 180 (6) 37663774. DOI: 10.4049/jimmunol.180.6.3766.Hallermalm K, Seki K, De Geer A et al. Modulation of the Tumor Cell Phenotype by IFN-y Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes. The Journal of Immunology March 15, 2008, 180 (6) 37663774. DOI: 10.4049/jimmunol.180.6.3766.Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016; 375 (18): 1767-1778. PMID: 27806234. DOI: 10.1056/NEJMra1514296.Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016; 375 (18): 1767-1778. PMID: 27806234. DOI: 10.1056/NEJMra1514296.Robertson AG, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018; 33 (1): 151. PMID: 28810145. DOI: 10.1016/j.ccell.2017.07.003.Robertson AG, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018; 33 (1): 151. PMID: 28810145. DOI: 10.1016/j.ccell.2017.07.003.Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD 155 in the Effector Phase. J Invest Dermatol. 2016; 136 (1): 255-263. PMID: 26763445. DOI: 10.1038/JID.2015.404.Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD 155 in the Effector Phase. J Invest Dermatol. 2016; 136 (1): 255-263. PMID: 26763445. DOI: 10.1038/JID.2015.404.Zhai L, Spranger S, Binder DC, et al. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015; 21 (24): 5427-5433. PMID: 26519060. DOI: 10.1158/1078-0432.CCR-15-0420.Zhai L, Spranger S, Binder DC, et al. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015; 21 (24): 5427-5433. PMID: 26519060. DOI: 10.1158/1078-0432.CCR-15-0420.Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015; 28 (2): 135-147. PMID: 25113308. DOI: 10.1111/pcmr.12304.Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015; 28 (2): 135-147. PMID: 25113308. DOI: 10.1111/pcmr.12304.Gezgin G, Luk SJ, Cao J, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol. 2017; 135 (6): 541-549. PMID: 28448663. DOI: 10.1001/jamaophthalmol.2017.0729.Gezgin G, Luk SJ, Cao J, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol. 2017; 135 (6): 541-549. PMID: 28448663. DOI: 10.1001/jamaophthalmol.2017.0729.Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723. DOI: 10.1056/ NEJMoa1003466.Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723. DOI: 10.1056/ NEJMoa1003466.Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013; 24 (11): 2911-2915. PMID: 24067719. DOI: 10.1093/annonc/mdt376.Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013; 24 (11): 2911-2915. PMID: 24067719. DOI: 10.1093/annonc/mdt376.Rodriguez J, de Olza M, Codes M et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. Journal of Clinical Oncology 2014 32:15_suppl, 90339033. DOI: 10.1200/jco.2014.32.15_suppl.9033.Rodriguez J, de Olza M, Codes M et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. Journal of Clinical Oncology 2014 32:15_suppl, 90339033. DOI: 10.1200/jco.2014.32.15_suppl.9033.Schadendorf D, Ascierto PA, Haanen JB et al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). J Clin Oncol 2017; 35. DOI: 10.1200/ JCO.2017.35.15_suppl.9524.Schadendorf D, Ascierto PA, Haanen JB et al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). J Clin Oncol 2017; 35. DOI: 10.1200/ JCO.2017.35.15_suppl.9524.Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373 (13): 1270-1271. PMID: 26398076. DOI:10.1056/NEJMc1509660.Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373 (13): 1270-1271. PMID: 26398076. DOI:10.1056/NEJMc1509660.Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122 (21): 3344-3353. PMID: 27533448. DOI: 10.1002/cncr.30258.Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122 (21): 3344-3353. PMID: 27533448. DOI: 10.1002/cncr.30258.Javed A, Arguello D, Johnston C, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017; 9 (16): 1323-1330. PMID: 29185395. DOI:10.2217/ imt-2017-0066.Javed A, Arguello D, Johnston C, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017; 9 (16): 1323-1330. PMID: 29185395. DOI:10.2217/ imt-2017-0066.Heppt MV, Heinzerling L, Kähler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017; 82:56-65. PMID: 28648699. DOI: 10.1016/j.ejca.2017.05.038.Heppt MV, Heinzerling L, Kähler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017; 82:56-65. PMID: 28648699. DOI: 10.1016/j.ejca.2017.05.038.Rothermel LD, Sabesan AC, Stephens DJ, et al. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clin Cancer Res. 2016; 22 (9): 2237-2249. PMID: 26712692. DOI: 10.1158/1078-0432. CCR-15-2294.Rothermel LD, Sabesan AC, Stephens DJ, et al. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clin Cancer Res. 2016; 22 (9): 2237-2249. PMID: 26712692. DOI: 10.1158/1078-0432. CCR-15-2294.Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017; 18 (6): 792-802. PMID: 28395880. DOI: 10.1016/S 1470-2045(17)30251-6.Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017; 18 (6): 792-802. PMID: 28395880. DOI: 10.1016/S 1470-2045(17)30251-6.Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol. 2015; 67 (2 Pt A): 67-74. PMID: 25708206. DOI: 10.1016/j. molimm.2015.01.024.Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol. 2015; 67 (2 Pt A): 67-74. PMID: 25708206. DOI: 10.1016/j. molimm.2015.01.024.Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother. 2014; 63 (5): 437-448. PMID: 24531387. DOI: 10.1007/ s00262-014-1525-z.Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother. 2014; 63 (5): 437-448. PMID: 24531387. DOI: 10.1007/ s00262-014-1525-z.Middleton M, Steven N, Evans T et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-an-tiCD 3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. Journal of Clinical Oncology 2016 34:15_suppl, 3016-3016. DOI: 10.1200/ JCO.2016.34.15_suppl.3016.Middleton M, Steven N, Evans T et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-an-tiCD 3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. Journal of Clinical Oncology 2016 34:15_suppl, 3016-3016. DOI: 10.1200/ JCO.2016.34.15_suppl.3016.Iams WT, Sosman JA, Chandra S. Novel Targeted Therapies for Metastatic Melanoma. Cancer J. 2017; 23 (1): 54-58. PMID: 28114255. DOI: 10.1097/PPO.0000000000000242.Iams WT, Sosman JA, Chandra S. Novel Targeted Therapies for Metastatic Melanoma. Cancer J. 2017; 23 (1): 54-58. PMID: 28114255. DOI: 10.1097/PPO.0000000000000242.

The authors declare that there are no conflicts of interest present.